

Didanosine
Removed
General description

INN
Didanosine
ATC codes

[J05AF02](#)
Medicine type
Chemical agent
EML status history
First added in 2002 ([TRS 914](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Removed in 2015 ([TRS 994](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia
[Didanosine](#)

DrugBank
[Didanosine](#)

Recommendations

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)